Squalene-chidamide Prodrug
Squalene-chidamide Prodrug - Related Videos
01:30
Prodrugs
0 Views •
2023
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration. Prodrugs help overcome...
08:54
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
0 Views •
2023
This protocol describes the fabrication and characterization of a photoresponsive prodrug-dye nanoassembly. The methodology for drug release from the nanoparticles by light-triggered disassembly, including the light irradiation setup, is explicitly described. The drugs released from the nanoparticles following light irradiation exhibited excellent anti-proliferation effects on human colorectal tumor cells.
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
0 Views •
Cited by 6 •
2017
This procedure will demonstrate how we synthesized and characterized the anti-NFκB and anti-cancer stem cell activity of an aspirin-fumarate prodrug.
01:50
Preparation of a Nanoemulsion Adjuvant Vaccine
0 Views •
2025
This video demonstrates the production of nanoemulsion tumor vaccines. The stable oil reservoir depots carrying synthetic peptides and adjuvants are produced by low-energy nanoemulsion, offering significant promise for tumor immunotherapy.
12:24
Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
0 Views •
2016
We present guidelines for developing synthetic 'chemical transducers' that can induce communication between naturally unrelated proteins. In addition, detailed protocols are presented for synthesizing and testing a specific 'transducer' that enables a growth factor to activate a detoxifying enzyme and consequently, to regulate the cleavage of an anticancer prodrug.
FAQs
Coupling chidamide to squalene changes more than the molecule’s composition: it creates an amphiphilic conjugate with both chidamide-associated pharmacological activity and lipid-like hydrophobic character. In aqueous environments, this balance drives spontaneous organization into nanoscale particles. That self-assembly can make the compound more suitable for delivery studies than a poorly water-soluble drug alone.
Squalene’s hydrophobicity is central to particle formation, while the chidamide portion retains the pharmacological feature being investigated. Together, the two parts allow the conjugate to behave differently from a freely dissolved small molecule in water. This division of roles provides a molecular basis for studying how formulation properties influence cellular uptake and delivery performance.
The conjugate is designed to potentially release chidamide under biological conditions, separating delivery behavior from eventual drug activity. Release matters because the system must preserve the advantages of nanoscale formulation while making chidamide available for its intended pharmacological action. In cancer research, this creates a way to examine how molecular presentation influences the performance of an epigenetic treatment.
Compared with chidamide considered on its own, the squalene-linked design addresses a different problem: how to formulate and deliver a poorly water-soluble compound. The conjugate adds hydrophobic, self-assembling behavior rather than simply relying on the parent drug’s properties. Researchers can therefore distinguish drug activity from effects arising from nanoscale organization and delivery.
Researchers can focus on formulation, particle formation, cellular uptake, and tumor-directed delivery as separate performance questions. These endpoints reflect different stages of the design: aqueous self-assembly, interaction with cells, and potential localization in tumors. Examining them separately helps determine which benefits result from squalene conjugation rather than from chidamide’s pharmacology alone.
A basic research workflow would begin by examining the conjugate in an aqueous environment to determine whether nanoscale particles form, followed by studies of biological-condition release and cellular uptake. Cancer-focused experiments can then consider tumor-directed delivery and pharmacological relevance. This sequence links physicochemical behavior to biological performance without assuming that particle formation alone proves therapeutic benefit.
The system is relevant to cancer research because chidamide supplies an epigenetic treatment context, whereas squalene supplies a delivery-oriented design element. This lets investigators study nanomedicine strategies alongside the pharmacology of a histone deacetylase inhibitor. The central outcome is whether improved formulation and uptake can potentially improve the therapeutic performance of an epigenetic treatment.